http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 19:53:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Ernexa+Therapeutics+Inc.++For%3A+Aug+04++Filed+by%3A+Polinsky+David/26991712.html si-local-file:///var/storage/secattach/20260827/26991712.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Ernexa+Therapeutics+Inc.++For%3A+Aug+04++Filed+by%3A+Polinsky+David/26991712.html Thu, 27 Aug 2026 19:53:00 -0400 ERNA O.00073229 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Ernexa+Therapeutics+Inc.++For%3A+Aug+04++Filed+by%3A+Polinsky+David/26991712.html si-local-file:///var/storage/secattach/20260827/26991712.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Ernexa+Therapeutics+Inc.++For%3A+Aug+04++Filed+by%3A+Polinsky+David/26991712.html Thu, 27 Aug 2026 19:53:00 -0400 ERNA O.00073229 http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985909.html <p align="center"><em>Video webcast now available </em><a href="https://www.globenewswire.com/Tracker?data=qSeFGJl96D9PT-QdEFgJ5FIxE8IpAOdmmLZ8WeQPiYg218ilK1KLVyXLzuonxRWfitSLs0KyqMhMYp-GXl9MfU-y7vZrEC2bqI0WloW9p3Y=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=chQOkqLUY8FAxuF9ZquOKR4S100iHbDjGARpm6ij0emG4nsezAZJF5lY6ZfTnpQ2e2DA7qteek-XYf1Et8BHVt8ZnvfGREGpA3AQgHWeKJg=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the <a href="https://www.globenewswire.com/Tracker?data=1udDmmf3PmjRrzAZG6R_frZT3e62oOp8_UxkpY1BhVwgc1kr1ebqjEqbRP98rQirdX6C0klymBjSut7g5y2Wqu0rxBZL0BYB8TD_atm4ItJ73n_1rqe-bdmQbbUqw_hfKinivM4ggxcaIJ34x0Wveg==" rel="nofollow" target="_blank">Virtual Investor "Why Now" on-demand conference</a>.</p> <p align="justify">During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned transition into a http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985909.html Thu, 27 Aug 2026 09:01:00 -0400 ERNA ERNA http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985909.html <p align="center"><em>Video webcast now available </em><a href="https://www.globenewswire.com/Tracker?data=qSeFGJl96D9PT-QdEFgJ5FIxE8IpAOdmmLZ8WeQPiYg218ilK1KLVyXLzuonxRWfitSLs0KyqMhMYp-GXl9MfU-y7vZrEC2bqI0WloW9p3Y=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=chQOkqLUY8FAxuF9ZquOKR4S100iHbDjGARpm6ij0emG4nsezAZJF5lY6ZfTnpQ2e2DA7qteek-XYf1Et8BHVt8ZnvfGREGpA3AQgHWeKJg=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the <a href="https://www.globenewswire.com/Tracker?data=1udDmmf3PmjRrzAZG6R_frZT3e62oOp8_UxkpY1BhVwgc1kr1ebqjEqbRP98rQirdX6C0klymBjSut7g5y2Wqu0rxBZL0BYB8TD_atm4ItJ73n_1rqe-bdmQbbUqw_hfKinivM4ggxcaIJ34x0Wveg==" rel="nofollow" target="_blank">Virtual Investor "Why Now" on-demand conference</a>.</p> <p align="justify">During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned transition into a http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985909.html Thu, 27 Aug 2026 09:01:00 -0400 ERNA ERNA http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985909.html <p align="center"><em>Video webcast now available </em><a href="https://www.globenewswire.com/Tracker?data=qSeFGJl96D9PT-QdEFgJ5FIxE8IpAOdmmLZ8WeQPiYg218ilK1KLVyXLzuonxRWfitSLs0KyqMhMYp-GXl9MfU-y7vZrEC2bqI0WloW9p3Y=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=chQOkqLUY8FAxuF9ZquOKR4S100iHbDjGARpm6ij0emG4nsezAZJF5lY6ZfTnpQ2e2DA7qteek-XYf1Et8BHVt8ZnvfGREGpA3AQgHWeKJg=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the <a href="https://www.globenewswire.com/Tracker?data=1udDmmf3PmjRrzAZG6R_frZT3e62oOp8_UxkpY1BhVwgc1kr1ebqjEqbRP98rQirdX6C0klymBjSut7g5y2Wqu0rxBZL0BYB8TD_atm4ItJ73n_1rqe-bdmQbbUqw_hfKinivM4ggxcaIJ34x0Wveg==" rel="nofollow" target="_blank">Virtual Investor "Why Now" on-demand conference</a>.</p> <p align="justify">During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned transition into a http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985909.html Thu, 27 Aug 2026 09:01:00 -0400 ERNA ERNA http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985909.html <p align="center"><em>Video webcast now available </em><a href="https://www.globenewswire.com/Tracker?data=qSeFGJl96D9PT-QdEFgJ5FIxE8IpAOdmmLZ8WeQPiYg218ilK1KLVyXLzuonxRWfitSLs0KyqMhMYp-GXl9MfU-y7vZrEC2bqI0WloW9p3Y=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=chQOkqLUY8FAxuF9ZquOKR4S100iHbDjGARpm6ij0emG4nsezAZJF5lY6ZfTnpQ2e2DA7qteek-XYf1Et8BHVt8ZnvfGREGpA3AQgHWeKJg=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the <a href="https://www.globenewswire.com/Tracker?data=1udDmmf3PmjRrzAZG6R_frZT3e62oOp8_UxkpY1BhVwgc1kr1ebqjEqbRP98rQirdX6C0klymBjSut7g5y2Wqu0rxBZL0BYB8TD_atm4ItJ73n_1rqe-bdmQbbUqw_hfKinivM4ggxcaIJ34x0Wveg==" rel="nofollow" target="_blank">Virtual Investor "Why Now" on-demand conference</a>.</p> <p align="justify">During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned transition into a http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%22Why+Now%22+On-Demand+Conference/26985909.html Thu, 27 Aug 2026 09:01:00 -0400 ERNA ERNA http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985923.html <p align="center"><em>Video webcast now available </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=qSeFGJl96D9PT-QdEFgJ5FIxE8IpAOdmmLZ8WeQPiYg218ilK1KLVyXLzuonxRWfitSLs0KyqMhMYp-GXl9MfU-y7vZrEC2bqI0WloW9p3Y=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=chQOkqLUY8FAxuF9ZquOKR4S100iHbDjGARpm6ij0emG4nsezAZJF5lY6ZfTnpQ2e2DA7qteek-XYf1Et8BHVt8ZnvfGREGpA3AQgHWeKJg=" rel="nofollow" target="_blank">Ernexa Therapeutics</a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1udDmmf3PmjRrzAZG6R_frZT3e62oOp8_UxkpY1BhVwgc1kr1ebqjEqbRP98rQirdX6C0klymBjSut7g5y2Wqu0rxBZL0BYB8TD_atm4ItJ73n_1rqe-bdmQbbUqw_hfKinivM4ggxcaIJ34x0Wveg==" rel="nofollow" target="_blank">Virtual Investor &quot;Why Now&quot; on-demand conference</a>.</p> <p align="justify">During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985923.html Thu, 27 Aug 2026 09:01:00 -0400 ERNA O.00073229 http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985923.html <p align="center"><em>Video webcast now available </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=qSeFGJl96D9PT-QdEFgJ5FIxE8IpAOdmmLZ8WeQPiYg218ilK1KLVyXLzuonxRWfitSLs0KyqMhMYp-GXl9MfU-y7vZrEC2bqI0WloW9p3Y=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=chQOkqLUY8FAxuF9ZquOKR4S100iHbDjGARpm6ij0emG4nsezAZJF5lY6ZfTnpQ2e2DA7qteek-XYf1Et8BHVt8ZnvfGREGpA3AQgHWeKJg=" rel="nofollow" target="_blank">Ernexa Therapeutics</a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1udDmmf3PmjRrzAZG6R_frZT3e62oOp8_UxkpY1BhVwgc1kr1ebqjEqbRP98rQirdX6C0klymBjSut7g5y2Wqu0rxBZL0BYB8TD_atm4ItJ73n_1rqe-bdmQbbUqw_hfKinivM4ggxcaIJ34x0Wveg==" rel="nofollow" target="_blank">Virtual Investor &quot;Why Now&quot; on-demand conference</a>.</p> <p align="justify">During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985923.html Thu, 27 Aug 2026 09:01:00 -0400 ERNA O.00073229 http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985923.html <p align="center"><em>Video webcast now available </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=qSeFGJl96D9PT-QdEFgJ5FIxE8IpAOdmmLZ8WeQPiYg218ilK1KLVyXLzuonxRWfitSLs0KyqMhMYp-GXl9MfU-y7vZrEC2bqI0WloW9p3Y=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=chQOkqLUY8FAxuF9ZquOKR4S100iHbDjGARpm6ij0emG4nsezAZJF5lY6ZfTnpQ2e2DA7qteek-XYf1Et8BHVt8ZnvfGREGpA3AQgHWeKJg=" rel="nofollow" target="_blank">Ernexa Therapeutics</a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1udDmmf3PmjRrzAZG6R_frZT3e62oOp8_UxkpY1BhVwgc1kr1ebqjEqbRP98rQirdX6C0klymBjSut7g5y2Wqu0rxBZL0BYB8TD_atm4ItJ73n_1rqe-bdmQbbUqw_hfKinivM4ggxcaIJ34x0Wveg==" rel="nofollow" target="_blank">Virtual Investor &quot;Why Now&quot; on-demand conference</a>.</p> <p align="justify">During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985923.html Thu, 27 Aug 2026 09:01:00 -0400 ERNA O.00073229 http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985923.html <p align="center"><em>Video webcast now available </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=qSeFGJl96D9PT-QdEFgJ5FIxE8IpAOdmmLZ8WeQPiYg218ilK1KLVyXLzuonxRWfitSLs0KyqMhMYp-GXl9MfU-y7vZrEC2bqI0WloW9p3Y=" rel="nofollow" target="_blank"><em>here</em></a></p> <p align="justify">CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=chQOkqLUY8FAxuF9ZquOKR4S100iHbDjGARpm6ij0emG4nsezAZJF5lY6ZfTnpQ2e2DA7qteek-XYf1Et8BHVt8ZnvfGREGpA3AQgHWeKJg=" rel="nofollow" target="_blank">Ernexa Therapeutics</a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1udDmmf3PmjRrzAZG6R_frZT3e62oOp8_UxkpY1BhVwgc1kr1ebqjEqbRP98rQirdX6C0klymBjSut7g5y2Wqu0rxBZL0BYB8TD_atm4ItJ73n_1rqe-bdmQbbUqw_hfKinivM4ggxcaIJ34x0Wveg==" rel="nofollow" target="_blank">Virtual Investor &quot;Why Now&quot; on-demand conference</a>.</p> <p align="justify">During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Participates+in+the+Virtual+Investor+%26quot%3BWhy+Now%26quot%3B+On-Demand+Conference/26985923.html Thu, 27 Aug 2026 09:01:00 -0400 ERNA O.00073229 http://www.streetinsider.com/Board+Changes/Ernexa+Therapeutics+adds+David+Polinsky+to+its+board+of+directors/26895364.html <p>Ernexa Therapeutics (NASDAQ: ERNA) has appointed David Polinsky to its board of directors, according to a press release from the Cambridge, Mass.-based cell therapy company.</p><p>Polinsky currently serves as chief financial officer of Rafael Holdings, where he oversees finance, legal, corporate strategy, and governance. He previously co-founded Cornerstone Pharmaceuticals, formerly known as Rafael Pharmaceuticals, where he held roles including president and general counsel, helping build the company from an early-stage startup into a clinical-stage oncology company.</p><p>At Rafael Holdings, Polinsky was involved in the company's 2018 spin-off as an independent NYSE-listed company, its 2025 merger with Cyclo Therapeutics, and a roughly $25 http://www.streetinsider.com/Board+Changes/Ernexa+Therapeutics+adds+David+Polinsky+to+its+board+of+directors/26895364.html Mon, 10 Aug 2026 09:02:21 -0400 ERNA http://www.streetinsider.com/Corporate+News/Ernexa+Therapeutics+adds+David+Polinsky+to+its+board+of+directors/26895364.html <p>Ernexa Therapeutics (NASDAQ: ERNA) has appointed David Polinsky to its board of directors, according to a press release from the Cambridge, Mass.-based cell therapy company.</p><p>Polinsky currently serves as chief financial officer of Rafael Holdings, where he oversees finance, legal, corporate strategy, and governance. He previously co-founded Cornerstone Pharmaceuticals, formerly known as Rafael Pharmaceuticals, where he held roles including president and general counsel, helping build the company from an early-stage startup into a clinical-stage oncology company.</p><p>At Rafael Holdings, Polinsky was involved in the company's 2018 spin-off as an independent NYSE-listed company, its 2025 merger with Cyclo Therapeutics, and a roughly $25 http://www.streetinsider.com/Corporate+News/Ernexa+Therapeutics+adds+David+Polinsky+to+its+board+of+directors/26895364.html Mon, 10 Aug 2026 09:02:21 -0400 ERNA http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html <p align="center"><em>Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&amp;A and corporate governance </em></p> <p align="center"><em>Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026</em></p> <p align="justify">CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YVxdGS4jlgbb-a0a9veavdMWjqtkodP2SEBRx0KJcpie9z3H4gnl1h-l4XWm-dV0m3kbxninHHVM-VXlhQuSZyzd3YDsCEMI-ST0tGeJUwc=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html Mon, 10 Aug 2026 09:01:00 -0400 ERNA ERNA RFL http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html <p align="center"><em>Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&amp;A and corporate governance </em></p> <p align="center"><em>Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026</em></p> <p align="justify">CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YVxdGS4jlgbb-a0a9veavdMWjqtkodP2SEBRx0KJcpie9z3H4gnl1h-l4XWm-dV0m3kbxninHHVM-VXlhQuSZyzd3YDsCEMI-ST0tGeJUwc=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html Mon, 10 Aug 2026 09:01:00 -0400 ERNA ERNA RFL http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html <p align="center"><em>Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&amp;A and corporate governance </em></p> <p align="center"><em>Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026</em></p> <p align="justify">CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YVxdGS4jlgbb-a0a9veavdMWjqtkodP2SEBRx0KJcpie9z3H4gnl1h-l4XWm-dV0m3kbxninHHVM-VXlhQuSZyzd3YDsCEMI-ST0tGeJUwc=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html Mon, 10 Aug 2026 09:01:00 -0400 ERNA ERNA RFL http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html <p align="center"><em>Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&amp;A and corporate governance </em></p> <p align="center"><em>Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026</em></p> <p align="justify">CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YVxdGS4jlgbb-a0a9veavdMWjqtkodP2SEBRx0KJcpie9z3H4gnl1h-l4XWm-dV0m3kbxninHHVM-VXlhQuSZyzd3YDsCEMI-ST0tGeJUwc=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html Mon, 10 Aug 2026 09:01:00 -0400 ERNA ERNA RFL http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html <p align="center"><em>Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&amp;A and corporate governance </em></p> <p align="center"><em>Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026</em></p> <p align="justify">CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YVxdGS4jlgbb-a0a9veavdMWjqtkodP2SEBRx0KJcpie9z3H4gnl1h-l4XWm-dV0m3kbxninHHVM-VXlhQuSZyzd3YDsCEMI-ST0tGeJUwc=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html Mon, 10 Aug 2026 09:01:00 -0400 ERNA ERNA RFL http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html <p align="center"><em>Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&amp;A and corporate governance </em></p> <p align="center"><em>Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026</em></p> <p align="justify">CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YVxdGS4jlgbb-a0a9veavdMWjqtkodP2SEBRx0KJcpie9z3H4gnl1h-l4XWm-dV0m3kbxninHHVM-VXlhQuSZyzd3YDsCEMI-ST0tGeJUwc=" rel="nofollow" target="_blank"><u>Ernexa Therapeutics</u></a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+Strengthens+Board+with+Veteran+Biotech+Executive+David+Polinsky+as+Company+Approaches+Clinical+Stage/26895326.html Mon, 10 Aug 2026 09:01:00 -0400 ERNA ERNA RFL http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Ernexa+Therapeutics+Inc.++For%3A+Jun+30/26885730.html si-local-file:///var/storage/secattach/20260806/26885730.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Ernexa+Therapeutics+Inc.++For%3A+Jun+30/26885730.html Thu, 06 Aug 2026 17:31:00 -0400 ERNA O.00073229 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Ernexa+Therapeutics+Inc.++For%3A+Jun+30/26885730.html si-local-file:///var/storage/secattach/20260806/26885730.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Ernexa+Therapeutics+Inc.++For%3A+Jun+30/26885730.html Thu, 06 Aug 2026 17:31:00 -0400 ERNA O.00073229 http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+CEO+Corner+Emphasizes+How+ERNA-101+Could+Help+Unlock+the+Next+Generation+of+Combination+Cancer+Therapies/26811390.html <p align="center"><em>CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically &quot;Cold&quot; Tumors Into Targets for the Immune System</em></p> <p align="center"><em> Video Showcases Differentiated Off-the-Shelf Cell Therapy Platform, Independent Validation of Complete Tumor Clearance in Preclinical Studies and Continued Execution Toward Planned IND Submission in Q3 2026</em></p> <p align="center"><em>Access the Ernexa CEO Corner </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=9nlc8avy1YelPkZ_9Bse8N4aOvBAPcjeA0D5FJwgTn-rnF3ciqm67GSo7zHDyYImhEp3hajxERA4Ka1Eth5SyD5wpuCWZ95fh3kUXUq6H3Q=" rel="nofollow" target="_blank"><em>here</em><strong> </strong></a></p> <p align="justify">CAMBRIDGE, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PCxy8WlI871v4bx1zm45nEIafIw79m4bdCPSkLZGK6adym8U27zUkSAOqSF3yJNrNBUEzQQiAbtwQ2q-98tpX2drwLP-ZC3ljFsejSedSdo=" rel="nofollow" target="_blank">Ernexa Therapeutics</a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+CEO+Corner+Emphasizes+How+ERNA-101+Could+Help+Unlock+the+Next+Generation+of+Combination+Cancer+Therapies/26811390.html Fri, 24 Jul 2026 09:20:00 -0400 ERNA O.00073229 http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+CEO+Corner+Emphasizes+How+ERNA-101+Could+Help+Unlock+the+Next+Generation+of+Combination+Cancer+Therapies/26811390.html <p align="center"><em>CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically &quot;Cold&quot; Tumors Into Targets for the Immune System</em></p> <p align="center"><em> Video Showcases Differentiated Off-the-Shelf Cell Therapy Platform, Independent Validation of Complete Tumor Clearance in Preclinical Studies and Continued Execution Toward Planned IND Submission in Q3 2026</em></p> <p align="center"><em>Access the Ernexa CEO Corner </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=9nlc8avy1YelPkZ_9Bse8N4aOvBAPcjeA0D5FJwgTn-rnF3ciqm67GSo7zHDyYImhEp3hajxERA4Ka1Eth5SyD5wpuCWZ95fh3kUXUq6H3Q=" rel="nofollow" target="_blank"><em>here</em><strong> </strong></a></p> <p align="justify">CAMBRIDGE, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PCxy8WlI871v4bx1zm45nEIafIw79m4bdCPSkLZGK6adym8U27zUkSAOqSF3yJNrNBUEzQQiAbtwQ2q-98tpX2drwLP-ZC3ljFsejSedSdo=" rel="nofollow" target="_blank">Ernexa Therapeutics</a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the http://www.streetinsider.com/Press+Releases/Ernexa+Therapeutics+CEO+Corner+Emphasizes+How+ERNA-101+Could+Help+Unlock+the+Next+Generation+of+Combination+Cancer+Therapies/26811390.html Fri, 24 Jul 2026 09:20:00 -0400 ERNA O.00073229 http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+CEO+Corner+Emphasizes+How+ERNA-101+Could+Help+Unlock+the+Next+Generation+of+Combination+Cancer+Therapies/26811390.html <p align="center"><em>CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically &quot;Cold&quot; Tumors Into Targets for the Immune System</em></p> <p align="center"><em> Video Showcases Differentiated Off-the-Shelf Cell Therapy Platform, Independent Validation of Complete Tumor Clearance in Preclinical Studies and Continued Execution Toward Planned IND Submission in Q3 2026</em></p> <p align="center"><em>Access the Ernexa CEO Corner </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=9nlc8avy1YelPkZ_9Bse8N4aOvBAPcjeA0D5FJwgTn-rnF3ciqm67GSo7zHDyYImhEp3hajxERA4Ka1Eth5SyD5wpuCWZ95fh3kUXUq6H3Q=" rel="nofollow" target="_blank"><em>here</em><strong> </strong></a></p> <p align="justify">CAMBRIDGE, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PCxy8WlI871v4bx1zm45nEIafIw79m4bdCPSkLZGK6adym8U27zUkSAOqSF3yJNrNBUEzQQiAbtwQ2q-98tpX2drwLP-ZC3ljFsejSedSdo=" rel="nofollow" target="_blank">Ernexa Therapeutics</a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+CEO+Corner+Emphasizes+How+ERNA-101+Could+Help+Unlock+the+Next+Generation+of+Combination+Cancer+Therapies/26811390.html Fri, 24 Jul 2026 09:20:00 -0400 ERNA O.00073229 http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+CEO+Corner+Emphasizes+How+ERNA-101+Could+Help+Unlock+the+Next+Generation+of+Combination+Cancer+Therapies/26811390.html <p align="center"><em>CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically &quot;Cold&quot; Tumors Into Targets for the Immune System</em></p> <p align="center"><em> Video Showcases Differentiated Off-the-Shelf Cell Therapy Platform, Independent Validation of Complete Tumor Clearance in Preclinical Studies and Continued Execution Toward Planned IND Submission in Q3 2026</em></p> <p align="center"><em>Access the Ernexa CEO Corner </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=9nlc8avy1YelPkZ_9Bse8N4aOvBAPcjeA0D5FJwgTn-rnF3ciqm67GSo7zHDyYImhEp3hajxERA4Ka1Eth5SyD5wpuCWZ95fh3kUXUq6H3Q=" rel="nofollow" target="_blank"><em>here</em><strong> </strong></a></p> <p align="justify">CAMBRIDGE, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PCxy8WlI871v4bx1zm45nEIafIw79m4bdCPSkLZGK6adym8U27zUkSAOqSF3yJNrNBUEzQQiAbtwQ2q-98tpX2drwLP-ZC3ljFsejSedSdo=" rel="nofollow" target="_blank">Ernexa Therapeutics</a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the http://www.streetinsider.com/Globe+Newswire/Ernexa+Therapeutics+CEO+Corner+Emphasizes+How+ERNA-101+Could+Help+Unlock+the+Next+Generation+of+Combination+Cancer+Therapies/26811390.html Fri, 24 Jul 2026 09:20:00 -0400 ERNA O.00073229 http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS